A generic version of Crestor—the final statin drug that enjoyed patent protection—was just approved by the FDA. This will benefit consumers and hurt AstraZeneca, the drug's inventor. It is unlikely that we will see any more new drugs from this class, which has proven cardiovascular benefits.
